title: trans-Resveratrol, an extract of red wine, inhibits human eosinophil activation and degranulation.
abstract: OBJECTIVE
  trans-Resveratrol, a non-flavonoid polyphenol found abundantly in red wine possesses antiproliferative and anti-inflammatory activity in various inflammatory disease conditions. However, the effect of trans-resveratrol on eosinophil activation in relation to allergy has not been investigated.
  
  
  METHODS
  Human eosinophils were isolated and purified from whole blood and incubated for 16 h with trans-resveratrol. Eosinophil chemotaxis, activation and degranulation, and apoptosis were investigated. The effect of trans-resveratrol on the inhibition of p38 and ERK1/2 activation was examined.
  
  
  RESULTS
  Treatment of human eosinophils with trans-resveratrol at concentrations <100 microM for 16 h did not induce eosinophil apoptosis. Similar results were seen after 24 h and 48 h incubations. trans-Resveratrol (<100 microM) significantly inhibited eosinophil peroxidase release after activation with IL-5 (IC(50)=2.9+/-0.9 microM) or C5a (IC(50)=3.9+/-0.5 microM) after 5 min priming with cytochalasin B (CB). Similarly, the production of leukotriene C4 after stimulation with calcium ionophore, and eosinophil chemotaxis in response to eotaxin, as well as CD11b upregulation and CD62 L shedding was also significantly reduced by trans-resveratrol, at concentrations above 5 microM. All the activators induced p38 and ERK1/2 phosphorylation maximal at 2 min of activation. trans-Resveratrol potently inhibited p38 and ERK1/2 activation after calcium ionophore and CB and C5a activation.
  
  
  CONCLUSIONS
  trans-Resveratrol is effective at inhibiting human eosinophil activation and degranulation at concentrations <100 microM, while not inducing apoptosis. This potent anti-inflammatory activity of trans-resveratrol and possibly its metabolites on eosinophils may be worth investigating for the treatment of eosinophil-related allergic diseases.
authors.affiliation: Inflammation and Cancer Laboratory, Department of Physiology and NUS Immunology Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
authors.forename: Y
authors.initials: Y
authors.lastname: Tan
authors.forename: L H K
authors.initials: LH
authors.lastname: Lim
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015550:Cell Degranulation / Q000187:drug effects*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D047209:Eosinophil Peroxidase / Q000187:drug effects / Q000378:metabolism; D004804:Eosinophils / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D020128:Inhibitory Concentration 50; D017997:Leukotriene C4 / Q000378:metabolism; D019950:Mitogen-Activated Protein Kinase 1 / Q000187:drug effects / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000187:drug effects / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors; D014920:Wine; D048051:p38 Mitogen-Activated Protein Kinases / Q000187:drug effects / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013267:Stilbenes; D017997:Leukotriene C4; D047209:Eosinophil Peroxidase; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D048051:p38 Mitogen-Activated Protein Kinases; D000077185:Resveratrol
references.citation: J Allergy Clin Immunol. 2001 Oct;108(4):503-8
references.pmid: 11590372
references.citation: Am Rev Respir Dis. 1991 Nov;144(5):1053-7
references.pmid: 1659268
references.citation: J Leukoc Biol. 1994 May;55(5):662-75
references.pmid: 8182345
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):953-7
references.pmid: 14578128
references.citation: J Allergy Clin Immunol. 1985 Oct;76(4):595-604
references.pmid: 4056248
references.citation: FASEB J. 2005 May;19(7):840-1
references.pmid: 15734790
references.citation: Int Immunopharmacol. 2003 Jun;3(6):845-52
references.pmid: 12781701
references.citation: Br Med Bull. 2000;56(4):985-1003
references.pmid: 11359633
references.citation: Am J Respir Cell Mol Biol. 2000 Jun;22(6):693-701
references.pmid: 10837366
references.citation: Blood. 2000 Mar 15;95(6):1911-7
references.pmid: 10706854
references.citation: N Engl J Med. 1990 Oct 11;323(15):1033-9
references.pmid: 2215562
references.citation: J Immunol. 2000 Aug 15;165(4):2198-204
references.pmid: 10925307
references.citation: J Allergy Clin Immunol. 1988 Apr;81(4):711-7
references.pmid: 3356850
references.citation: Br J Pharmacol. 2006 Apr;147(8):873-85
references.pmid: 16474422
references.citation: J Immunol. 1999 Aug 1;163(3):1611-8
references.pmid: 10415066
references.citation: Leukemia. 2001 Nov;15(11):1735-42
references.pmid: 11681415
references.citation: J Endocrinol. 2003 Jul;178(1):37-43
references.pmid: 12844334
references.citation: Br J Pharmacol. 1998 Apr;123(8):1691-9
references.pmid: 9605577
references.citation: J Exp Med. 1995 May 1;181(5):1827-34
references.pmid: 7722458
references.citation: Clin Exp Immunol. 2000 Apr;120(1):12-21
references.pmid: 10759758
references.citation: J Immunol. 2001 May 1;166(9):5763-72
references.pmid: 11313420
references.citation: J Allergy Clin Immunol. 1987 Mar;79(3):496-504
references.pmid: 3029204
references.citation: Lancet. 2000 Dec 23-30;356(9248):2144-8
references.pmid: 11191542
references.citation: J Pharmacol Exp Ther. 2002 Jul;302(1):369-73
references.pmid: 12065739
references.citation: J Immunol. 1989 Oct 1;143(7):2311-6
references.pmid: 2506282
references.citation: Proc Natl Acad Sci U S A. 1983 Dec;80(24):7626-30
references.pmid: 6324182
references.citation: Int J Mol Med. 2005 Feb;15(2):337-52
references.pmid: 15647852
references.citation: Drug Metab Dispos. 2004 Dec;32(12):1377-82
references.pmid: 15333514
references.citation: Eur J Cardiovasc Prev Rehabil. 2005 Dec;12(6):596-600
references.pmid: 16319551
references.citation: Adv Immunol. 1986;39:177-253
references.pmid: 3538819
references.citation: Physiol Res. 2003;52(5):555-62
references.pmid: 14535830
references.citation: Trends Pharmacol Sci. 1995 Sep;16(9):304-9
references.pmid: 7482995
references.citation: Expert Opin Investig Drugs. 2006 Oct;15(10):1191-200
references.pmid: 16989596
references.citation: J Clin Endocrinol Metab. 2002 Mar;87(3):1223-32
references.pmid: 11889192
references.citation: Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L774-83
references.pmid: 15180920
references.citation: Clin Biochem. 2003 Feb;36(1):79-87
references.pmid: 12554065
references.citation: Cancer Lett. 1999 Jun 1;140(1-2):1-10
references.pmid: 10403535
references.citation: FASEB J. 2003 Nov;17(14):1975-85
references.pmid: 14597667
references.citation: Eur J Clin Invest. 2003 Sep;33(9):818-23
references.pmid: 12925042